Myriad Genetics (MYGN) Stock News
$MYGN · NASDAQ · 2 stories in 30 daysBORSA has published 2 stories on Myriad Genetics (MYGN) in the past 30 days. BORSA’s news read on MYGN is bullish at 60/100, unchanged over 24 hours, based on 1 company event over the past 7 days. Myriad Genetics’ next earnings report is scheduled for Monday, Nov 2.
The wire on $MYGN
newest first · updated · direct subject stories onlyTD Cowen lifts Myriad Genetics price target to $4.50
TD Cowen increased its price target for Myriad Genetics to $4.50 per share.
bullish 65 · impact 30Myriad Genetics and SOPHiA GENETICS partner to advance prostate genomic instability score technology
The two companies are collaborating to advance Prostate Genomic Instability Score technology.
neutral 50 · impact 30The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card